Playback speed
10 seconds
ESMO 2022 on the Phase 3 RATIONALE-301 Study: Tislelizumab OS Benefit vs. Sorafenib as 1L Treatment for Unresectable HCC
By
ecancer
FEATURING
Richard S. Finn
By
ecancer
FEATURING
Richard S. Finn
37 views
September 30, 2022
Comments 0
Login to view comments.
Click here to Login